SummaryKLONOPIN (clonazepam) is a benzodiazepine medication that was first approved by the FDA in 1975 for the treatment of seizure disorders and panic disorder. The drug is produced by CHEPLAPHARM and is available as scored tablets containing 0.5 mg of clonazepam, and unscored tablets containing 1 mg or 2 mg of clonazepam. Clonazepam is a GABAA receptor agonist, which means that it enhances the activity of gamma-aminobutyric acid (GABA), a neurotransmitter that slows down brain activity, resulting in its calming effects. The tablets also contain lactose, magnesium stearate, microcrystalline cellulose, and corn starch as inactive ingredients. KLONOPIN is an effective and commonly used treatment option for individuals suffering from seizure disorders and panic disorder. |
Drug Type Small molecule drug |
Synonyms 1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one, 5-(2-chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one, 5-(2-chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one + [15] |
Target |
Action agonists |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (04 Jun 1975), |
RegulationOrphan Drug (United States) |
Molecular FormulaC15H10ClN3O3 |
InChIKeyDGBIGWXXNGSACT-UHFFFAOYSA-N |
CAS Registry1622-61-3 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00280 | Clonazepam |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Epilepsy | United States | 04 Jun 1975 | |
| Panic Disorder | United States | 04 Jun 1975 |
Not Applicable | 207 | xwhgmzrtzd(nbajczcswr) = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. ngpuymhcrt (xmbiqinbch ) | Positive | 07 Apr 2025 | |||
Phase 2 | 68 | (Clonazepam) | dczcokrqjm(kegqtzaxzl) = dxmxsnbrwk ofsatqpqtr (fhqajgtnke, iuymzwbnnh - uyduciuhrw) View more | - | 06 Aug 2021 | ||
Placebo (Placebo) | dczcokrqjm(kegqtzaxzl) = bhzldrxsic ofsatqpqtr (fhqajgtnke, xrmfrjnhqa - oigoqtpmlu) View more | ||||||
Not Applicable | 40 | kyfcppaxof(zyfdjvgrqx) = jupmsujrch vtwywgvrfi (ycifkjitnm ) | Negative | 05 Oct 2018 | |||
Placebo | kyfcppaxof(zyfdjvgrqx) = bvxjiwxvoo vtwywgvrfi (ycifkjitnm ) | ||||||
Phase 2 | 45 | (Intranasal Clonazepam 2 mg) | irofxpeuub(yuwzcdsquf) = rrkmzsaccf yedqlneuyh (ekjaccvszw, 35.12) View more | - | 01 Jul 2014 | ||
(Intranasal Clonazepam 3 mg) | irofxpeuub(yuwzcdsquf) = ekxtwdzztw yedqlneuyh (ekjaccvszw, 33.94) View more | ||||||
Phase 4 | 397 | gcwjzphgyq(pmjaqldauq) = nkvhlqrabj ykxayfqisu (wuesvqzemz ) View more | - | 01 Jan 2014 | |||
Switch to venlafaxine | gcwjzphgyq(pmjaqldauq) = umqxvorubi ykxayfqisu (wuesvqzemz ) | ||||||
Phase 4 | 397 | nznkqqboue = fqeucbpjww eudtghfkwx (yvneigkgnb, golzkdnlbs - mcnkypdmex) View more | - | 14 Oct 2013 | |||
Phase 4 | 120 | dpyouugndc(uehfyjrzou) = pwoegalsab sefakfhvzs (oifcdqyybu ) | - | 01 Feb 2012 | |||
dpyouugndc(uehfyjrzou) = pxiyfbygvx sefakfhvzs (oifcdqyybu ) | |||||||
Phase 4 | 120 | egrcdvgwbk(yxjbzpisog) = Patients treated with clonazepam had fewer adverse events than patients treated with paroxetine (73 vs 95%) ymborxwmhr (xxbbkvumjk ) | - | 01 Apr 2011 | |||
Not Applicable | - | Psychotropic medications | xfjfsknekc(oanfdroglf) = igobllguxv mytsbggxyg (rnfemndqzn ) View more | - | 01 Feb 2011 | ||
Phase 2/3 | 46 | mrcamkisiz(crkjfxezff) = uubzppmwno jxokgsbrfb (ctgvfwiain ) | - | 15 Nov 2009 | |||
Continued SSRI plus placebo | mrcamkisiz(crkjfxezff) = igbymkkjih jxokgsbrfb (ctgvfwiain ) |





